Preclinical toxicity studies supporting 2DG for treatment of status epilepticus
Epilepsy & Behavior · 2024
DOI: 10.1016/j.yebeh.2024.110004 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Epilepsy & Behavior, 2024. Verfasst von Thomas P Sutula und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, University of Wisconsin, Madison WI, USA; Hexokine Therapeutics, Inc. Madison WI, USA. Electronic address: sutula@neurology.…. Hauptthemen laut MEDLINE: Status Epilepticus, Deoxyglucose. Die Arbeit nennt 12 Literaturangaben.
Abstract (Originalsprache)
2-deoxy-D-glucose (2DG) has been proposed as a potential antiseizure treatment based on seizure suppressive actions in multiple acute and chronic seizure models, including models of status epilepticus (SE). Here we summarize recently completed preclinical toxicological studies of single doses of an intravenous formulation of 2DG supporting potential safety of 2DG for acute treatment of SE and acute repetitive seizures (ARS).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurology, University of Wisconsin, Madison WI, USA; Hexokine Therapeutics, Inc. Madison WI, USA. Electronic address: sutula@neurology.wisc.edu.
- Department of Neurology, F.E. Dreifuss Comprehensive Epilepsy Program, University of Virginia, Charlottesville VA, USA; Hexokine Therapeutics, Inc. Madison WI, USA.
Zitieren
APA
Sutula, T. P., & Fountain, N. B. (2024). Preclinical toxicity studies supporting 2DG for treatment of status epilepticus. Epilepsy & Behavior. https://doi.org/10.1016/j.yebeh.2024.110004
Vancouver
Sutula TP, Fountain NB. Preclinical toxicity studies supporting 2DG for treatment of status epilepticus. Epilepsy & Behavior. 2024. doi:10.1016/j.yebeh.2024.110004
BibTeX
@article{Sutula2024,
author = {Sutula, Thomas P and Fountain, Nathan B},
title = {Preclinical toxicity studies supporting 2DG for treatment of status epilepticus},
journal = {Epilepsy & Behavior},
year = {2024},
doi = {10.1016/j.yebeh.2024.110004}
}
EUVIMED